Order Article Reprints

Eskelinen V, Nivakoski E, Launonen K, Partanen A, Kakko S, Kuusisto MEL. First-Line Combination with Proteasome Inhibitor-Based Treatment and Zoledronic Acid Is Effective in Reducing Later Fractures in Multiple Myeloma Irrespective of Multiple Myeloma Bone Disease at Diagnosis. Hematology Reports. 2024; 16(3):529-540. https://doi.org/10.3390/hematolrep16030051

Eskelinen, Veera, Elise Nivakoski, Kirsi Launonen, Anu Partanen, Sakari Kakko, and Milla E. L. Kuusisto. 2024. "First-Line Combination with Proteasome Inhibitor-Based Treatment and Zoledronic Acid Is Effective in Reducing Later Fractures in Multiple Myeloma Irrespective of Multiple Myeloma Bone Disease at Diagnosis" Hematology Reports 16, no. 3: 529-540. https://doi.org/10.3390/hematolrep16030051

Eskelinen, V., Nivakoski, E., Launonen, K., Partanen, A., Kakko, S., & Kuusisto, M. E. L. (2024). First-Line Combination with Proteasome Inhibitor-Based Treatment and Zoledronic Acid Is Effective in Reducing Later Fractures in Multiple Myeloma Irrespective of Multiple Myeloma Bone Disease at Diagnosis. Hematology Reports, 16(3), 529-540. https://doi.org/10.3390/hematolrep16030051